Hurley John Joseph 4

What Happened

• John Joseph Hurley, Principal Accounting Officer at Avanos Medical (AVNS), reported the vesting/conversion of 919 performance-based restricted share units (PRSUs) on March 6, 2026. The conversion/receipt is reported as an exercise/conversion of a derivative: 919 shares were acquired at an implicit price/value of $13.79 per share (total value $12,673).
• To satisfy tax withholding obligations, Hurley surrendered/disposed of three blocks of shares on the same date: 321 shares ($4,427), 144 shares ($1,986), and 211 shares ($2,910), for a total surrendered value of $9,323. Net result: 243 shares retained (919 acquired − 676 surrendered), with a net value of about $3,351 at $13.79/share.

Key Details

• Transaction date: March 6, 2026; Filing date: March 10, 2026 (filed timely).
• Prices reported: $13.79 per share for the conversion and for the share withholding transactions.
• Shares acquired: 919 (conversion of PRSUs); shares surrendered/disposed: 321, 144, and 211 (total 676).
• Net shares added to beneficial ownership: 243 (919 − 676), net value ≈ $3,351.
• Footnotes: F1 = 919 PRSUs awarded 3/6/2023 and vested 3/6/2026 (each PRSU = 1 share). F2–F4 = shares were surrendered to the issuer to satisfy tax withholding on vested awards (covers PRSUs and time-based RSUs awarded on 3/6/2023 and 3/6/2024).
• Shares owned after the transaction are not disclosed in the provided excerpt.

Context

• This was a vesting/conversion event (derivative conversion of RSUs/PRSUs), not an open-market purchase or discretionary sale. The surrendered shares represent a typical "sell-to-cover" or share surrender to satisfy tax withholding on vesting — a routine administrative step rather than an active decision to lock in gains.
• Such restricted-unit vesting and tax-withholding share surrenders are common and do not necessarily indicate insider sentiment about the company’s stock.